About: Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
Creator	Liu, Bin Li, Xiaobo Xie, C Pan, Weiqi Li, Chufang Zhao, Jin Yang, Zifeng Jiang, Haiming Li, Runfeng Huang, Jicheng Shi, Yongxia Zheng, Kui Dai, Jun Li, Liu Li, Ma Liu D #, Bin Ma, Qinhai Shen, Liu Shi, Huang Wang, Zhoulang Xie, Yuqi
Source	Elsevier; Medline; PMC; WHO
abstract	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide through person-to-person contact, causing a public health emergency of international concern. At present, there is no specific antiviral treatment recommended for SARS-CoV-2 infection. Liu Shen capsule (LS), a traditional Chinese medicine, has been proven to have a wide spectrum of pharmacological properties, such as anti-inflammatory, antiviral and immunomodulatory activities. However, little is known about the antiviral effect of LS against SARS-CoV-2. Herein, the study was designed to investigate the antiviral activity of SARS-CoV-2 and its potential effect in regulating the host’s immune response. The inhibitory effect of LS against SARS-CoV-2 replication in Vero E6 cells was evaluated by using the cytopathic effect (CPE) and plaque reduction assay. The number of virions of SARS-CoV-2 was observed under transmission electron microscope after treatment with LS. Proinflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quantitative PCR assays. The results showed that LS could significantly inhibit SARS-CoV-2 replication in Vero E6 cells, and reduce the number of virus particles and it could markedly reduce pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-8, CCL-2/MCP-1 and CXCL-10/IP-10) production at the mRNA levels. Moreover, the expression of the key proteins in the NF-κB/MAPK signaling pathway was detected by western blot and it was found that LS could inhibit the expression of p-NF-κB p65, p-IκBα and p-p38 MAPK, while increasing the expression of IκBα. These findings indicate that LS could inhibit SARS-CoV-2 virus infection via downregulating the expression of inflammatory cytokines induced virus and regulating the activity of NF-κB/MAPK signaling pathway in vitro, making its promising candidate treatment for controlling COVID-19 disease.
has issue date	2020-04-30(xsd:dateTime)
bibo:doi	10.1016/j.phrs.2020.104850
bibo:pmid	32360580
has license	no-cc
sha1sum (hex)	69382cbac0bbdd2437414b92b122815b44d4cf46
schema:url	https://doi.org/10.1016/j.phrs.2020.104850
resource representing a document's title	Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
has PubMed Central identifier	PMC7192119
has PubMed identifier	32360580
schema:publication	Pharmacol Res
resource representing a document's body	covid:69382cbac0bbdd2437414b92b122815b44d4cf46#body_text
is schema:about of	named entity 'anti-inflammatory' named entity 'NF-κB' named entity 'anti-inflammatory' named entity 'signaling pathway' named entity 'Liu' named entity 'antiviral' named entity 'NF-B' named entity 'signaling pathway' named entity 'SARS-CoV-2' named entity 'coronavirus' named entity 'TEM' named entity 'virus' named entity 'antiviral' named entity 'antiviral treatment' named entity 'Suzhou' named entity 'Vero E6' named entity 'virus entry' named entity 'Dulbecco's modified Eagle's medium' named entity 'TCID50' named entity 'inflammation' named entity 'IL-6' named entity 'virus' named entity 'ICU' named entity 'antiviral activity' named entity 'pro-inflammatory' named entity 'cell death' named entity 'SARS-CoV-2' named entity 'Coronaviruses' named entity 'Huh-7' named entity 'aetiology' named entity 'NF-κB' named entity 'infection' named entity 'IFN-γ' named entity 'Thermo Fisher' named entity 'transcription factor' named entity 'p38 MAPK' named entity 'CCL-2' named entity 'anserine' named entity 'MERS-CoV' named entity 'antiviral' named entity 'ICU' named entity 'IκBα' named entity 'coronaviruses' named entity 'infection' named entity 'Vero E6' named entity 'Vero E6' named entity 'virus' named entity 'Wuhan' named entity 'MAPK signaling pathway' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'immune response' named entity 'PBS' named entity 'cytokines' named entity 'significant difference' named entity 'IFN-γ' named entity 'Vero E6' named entity 'viruses' named entity 'infection' named entity 'viruses' named entity 'pneumonia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software